Dedicated to the memory of microbiome research pioneer Vladimir Mouraviev, MD, PhD
There is an abundance of evidence that the human microbiome plays an important and nuanced role in controlling human health, including metabolism, immunity, pain, psychological state, and cancer. The recent discovery of the human genitourinary microbiome’s existence has led to the investigation of its role in mediating the pathogenesis of urinary tract infections, urologic pain syndromes, lower urinary tract symptoms, urolithiasis, and genitourinary malignancies like bladder, kidney, and prostate cancers. Furthermore, although it is largely recognized that members of the gastrointestinal microbiota are actively involved in drug metabolism, new studies demonstrate additional roles of the gastrointestinal microbiota (and their communication with the urinary microbiome) in dictating treatment response for urologic conditions, such as cancer.
There is now a host of evidence for a unique genitourinary (GU) microbiome. Translating microbiome research into clinical action will require incorporation of microbiome surveillance into ongoing and future clinical trials, as well as an expansion of studies to include metagenomic sequencing and metabolomics. In this learning center, we will review the most current research investigating a link between the gut and genitourinary microbiome and urologic disease. We will also focus on urologic infections and improving our understanding and treatment of them.
This learning center will provide information about our current and evolving state of knowledge with respect to our microbiome and its clinical impact on urologic disease. Our hope is that this expanding awareness of our urology microbiome will allow us to present clinically meaningful management strategies for the practicing physician.
Before exploring the range of topics in this learning center related to the microbiome and urologic infections, watch the below foundation lectures from J. Curtis Nickel, MD, FRCSC. Part 3 coming soon.
In the first of three foundational lectures, J. Curtis Nickel, MD, FRCSC, discusses the urology community’s evolving understanding of the urinary microbiome’s role in promoting urinary health.
J. Curtis Nickel, MD, FRCSC, discusses possible ways to manipulate the microbiome to promote urologic health and manage disease.
Nazema Y. Siddiqui, MD, MHSc, presented “Overactive Bladder (OAB) / Urge Urinary Incontinence (UUI) & the Urinary Microbiome” for the Grand Rounds in Urology audience in July 2020.
Priya N. Werahera, PhD, presented this lecture during the 30th Annual International Prostate Cancer Update on January 23, 2020, in Avon, Colorado.
Jennifer T. Anger, MD, MPH, and A. Lenore Ackerman, MD, PhD, presented “Recurrent Uncomplicated Urinary Tract Infections in Women: AUA/CUA/SUFU Guideline 2019” for the Grand Rounds in Urology audience in May, 2020.
Rick Martin, presented this lecture during the 30th Annual International Prostate Cancer Update on January 23, 2020, in Avon, Colorado.
Dr. Ackerman is Assistant Professor of Surgery, Urology and Pelvic Medicine and Reconstructive Surgery at Cedars-Sinai Medical Center, as well as Adjunct Assistant Professor of Urology in the Department of Surgery, Division of Urology at the David Geffen School of Medicine at UCLA Health. Her current research focuses on the role of host-microbe interactions in the etiology of benign lower urinary tract disorders. She now specializes in the treatment of incontinence, voiding dysfunction, and pelvic floor disorders at Cedars-Sinai Medical Center in Los Angeles.